Phio Pharmaceuticals enters ATM offering agreement with H.C. Wainwright for up to $6.36M

Phio Pharmaceuticals Corp.

Agreement allows sale of up to $6,360,000 of common stock via H.C. Wainwright as sales agent on an at-the-market basis.
H.C. Wainwright receives a 3.0% commission on gross proceeds; company reimburses up to $75,000 in legal fees.
No obligation to sell any shares; sales are made on Nasdaq Capital Market with T+1 settlement.
Company provides customary indemnification to the sales agent under the agreement.
The offering is registered under the company's existing S-3 shelf registration statement effective July 1, 2024.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.